Title:
COMPOSITION, COMPRISING TUSSILAGONE COMPOUND ISOLATED FROM TUSSILAGO FARFARA L. EXTRACT, FOR PREVENTION AND TREATMENT OF CANCER AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/221453
Kind Code:
A1
Abstract:
The present invention relates to a composition for prevention and treatment of cancer, which comprises the tussilagone compound isolated from a Tussilago farfara L. extract. In assays of tussilagone: for an effect on the viability of glioblastoma multiforme (experimental example 1); for an effect on the proliferation of the human glioblastoma cell lines U87MG and T98G (experimental example 2); for inhibitory potential against the production of the cell energy source ATP (experimental example 3); for an effect on the membrane potential of intracellular mitochondria (experimental example 4); for an effect on the formation of tumor spheres (experimental example 5); for an effect on the three-dimensional invasion of tumor spheres (experimental example 6); and for an effect on the protein expression of FoxM1 and MGMT (experimental example 7) according to the present invention, it was found that the sample of the present invention can overcome the problem with Temodal (temozolomide, TMZ), which is currently used as a unique therapeutic agent for brain cancer, and has a more potent anticancer activity and a FoxM1 inhibition mechanism as a critical mechanism surmounting resistance, thereby overcoming the resistance problem. Being identified not only to be used as an anticancer agent as a substituent for a conventional anticancer agent such as Temodal, but also to be administered in combination of a conventional anticancer agent, with the resultant subjugation of resistance thereto, the composition can be useful as a pharmaceutical composition for prevention and treatment of cancerous disease, a health functional food, and a health food supplement.
Inventors:
RYU JAE-HA (KR)
LI HUA (KR)
KANG SEOK GU (KR)
LI HUA (KR)
KANG SEOK GU (KR)
Application Number:
PCT/KR2019/005609
Publication Date:
November 21, 2019
Filing Date:
May 10, 2019
Export Citation:
Assignee:
UNIV SOOKMYUNG WOMENS IND ACAD COOP FOUND (KR)
UNIV YONSEI IACF (KR)
UNIV YONSEI IACF (KR)
International Classes:
A61K31/215; A23L33/10; A61K31/4188; A61K45/06; A61P35/00
Foreign References:
| KR20150033978A | 2015-04-02 | |||
| KR20070008228A | 2007-01-17 |
Other References:
LI, H. ET AL.: "Tussilagone suppresses colon cancer cell proliferation by promoting the degradation of beta-catenin", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 443, 2014, pages 132 - 137
PARK. Y. ET AL.: "Tussilagone inhibits dendritic cell functions via induction of heme oxygenase-1", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 22, 2014, pages 400 - 408, XP029060406, DOI: 10.1016/j.intimp.2014.07.023
HWANGBO, C. ET AL.: "The anti-inflammatory effect of tussilagone, from Tussilago farfara, is mediated by the induction of heme oxygenase-] in murine macrophages", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 9, 2009, pages 1578 - 1584, XP026741029, DOI: 10.1016/j.intimp.2009.09.016
PARK. Y. ET AL.: "Tussilagone inhibits dendritic cell functions via induction of heme oxygenase-1", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 22, 2014, pages 400 - 408, XP029060406, DOI: 10.1016/j.intimp.2014.07.023
HWANGBO, C. ET AL.: "The anti-inflammatory effect of tussilagone, from Tussilago farfara, is mediated by the induction of heme oxygenase-] in murine macrophages", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 9, 2009, pages 1578 - 1584, XP026741029, DOI: 10.1016/j.intimp.2009.09.016
Attorney, Agent or Firm:
SHIN, Dong In (KR)
Download PDF:
Previous Patent: AWNING TYPE SOLAR CELL MODULE POWER GENERATION APPARATUS
Next Patent: TRACKER ASSEMBLY AND TRACKER-REMOVING APPARATUS
Next Patent: TRACKER ASSEMBLY AND TRACKER-REMOVING APPARATUS